{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-127029","form_type":"8-K","ticker":"KOD","cik":"0001468748","company_name":"Kodiak Sciences Inc.","filed_at":"2024-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.511689+00:00","generated_at":"2026-05-30T00:25:21.398398+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Kodiak Sciences Q3 net loss $43.9M, cash $197.9M; provides pipeline updates","bullets":["Net loss of $43.9M ($0.84/sh) vs $50.0M ($0.95/sh) in Q3 2023; cash $197.9M expected to fund operations into 2026.","Phase 3 GLOW2 (diabetic retinopathy) and DAYBREAK (wet AMD) enrolling; enrollment completion targeted H1 2025.","KSI-101 APEX study enrolling; dose selection for pivotal studies expected Q2 2025.","Tarcocimab ocular half-life 20 days (3x faricimab, 2-3x aflibercept) presented at Sept R&D Day.","Preclinical ABCD pipeline expanded to glaucoma and geographic atrophy programs."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-127029","json":"https://secwatch.observer/filing/0000950170-24-127029.json","markdown":"https://secwatch.observer/filing/0000950170-24-127029.md","text":"https://secwatch.observer/filing/0000950170-24-127029.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1468748/000095017024127029/0000950170-24-127029-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1468748/000095017024127029/kod-20241114.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T00:25:21.398398+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}